{
  "docId": "019de071-3fcc-709d-bd81-493d670a1b54",
  "docSlug": "75c0ef2784bf914c01a48398bea9ca14",
  "documentTitle": "Caribou Biosciences | IPO Presentation Deck | 44 slides",
  "authorId": "caribou-biosciences",
  "authorName": "Caribou Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7744917,
  "pageNumber": 8,
  "pageCount": 44,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a visual comparison framework to contrast traditional autologous therapy with the company's allogeneic focus.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-3fcc-709d-bd81-493d670a1b54/8",
  "deckHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54",
  "deckJsonHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54.json",
  "deckAnchorHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.25,
        "y": 0.25
      },
      "kind": "image",
      "text": "Diagrams showing patient-to-cell flow for autologous vs donor-to-patient flow for allogeneic",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d220aa3-54e9-4169-8c7c-d18542b62174",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Autologous therapy vs Allogeneic therapy comparison points",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e257b49-f9ec-4dd8-a950-22e5ea7a053b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "We believe persistence is the key to unlocking the full potential of allogeneic cell therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8b3f77c-964d-4408-aa2d-0310849af9dc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "9a1a7e23-ec84-46a8-a8b4-f18384f462f4",
      "evidence": "Side-by-side comparison of two therapy types",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "630e1d28-eeca-4ead-af41-7557fcaa17ed",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The solution is presented on pages 7-14",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "24942973-5728-4b19-9656-9170f2cce1f1",
      "evidence": "The loop follows the golden circle structure",
      "position": 1,
      "objective": "To explain the why, how, and what of chRDNA technology",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}